PMID- 30284288
OWN - NLM
STAT- MEDLINE
DCOM- 20190325
LR  - 20190325
IS  - 1537-2995 (Electronic)
IS  - 0041-1132 (Linking)
VI  - 58
IP  - 11
DP  - 2018 Nov
TI  - Long-term monitoring of virus antibody titers in human intravenous immunoglobulin 
      lots derived from donors in Japan.
PG  - 2617-2626
LID - 10.1111/trf.14908 [doi]
AB  - BACKGROUND: Intravenous immunoglobulin (IVIG) contains immunoglobulin G against 
      various viruses, except those that have been screened, such as human 
      immunodeficiency and hepatitis C viruses. Antivirus titers reflect the serostatus 
      of the blood donor population in the collection region and are of clinical 
      interest. STUDY DESIGN AND METHODS: During the past 10 years, measles, mumps, 
      rubella, varicella-zoster, hepatitis A and B, Epstein-Barr, and human respiratory 
      syncytial viruses; human parainfluenza viruses 1, 2, and 3; human herpes simplex 
      viruses 1 and 2; human herpesvirus 6; cytomegalovirus (CMV); human adenoviruses 
      (HAdVs) 1, 2, 3, 7, and 11; human parvovirus B19; and human echovirus 9 and 11 
      titers in IVIG lots have been measured by a commercial testing facility. A viral 
      neutralizing assay for CMV has been used at our facility. Herein, we summarize 
      the measurements and results of a regression analysis of the trends in virus 
      antibody titers. RESULTS: IVIG lots contained significant titers against all of 
      the above viruses, except for HAdV 7. Three patterns-stable, increasing, and 
      decreasing-were observed, without any drastic changes. Although these trends 
      reflect the seroprevalence in Japan, the titers were not obviously affected by 
      the cycle of epidemics. On the other hand, the prevalence data suggest that 
      titers against hepatitis A virus and other viruses will decrease in the near 
      future, although they are currently stable. CONCLUSION: Monitoring the titer of 
      IVIG lots and seroprevalence of donor populations is important for anticipating 
      future changes in virus antibody titers of IVIG lots and can provide useful 
      information of clinical interest.
CI  - (c) 2018 AABB.
FAU - Onodera, Hiroyuki
AU  - Onodera H
AD  - Medical Information Department, Japan Blood Products Organization, Tokyo, Japan.
FAU - Nakagawa, Risa
AU  - Nakagawa R
AD  - Medical Information Department, Japan Blood Products Organization, Tokyo, Japan.
FAU - Nakagawa, Hitoshi
AU  - Nakagawa H
AD  - Research and Development Division, Japan Blood Products Organization, Tokyo, 
      Japan.
FAU - Urayama, Takeru
AU  - Urayama T
AD  - Research and Development Division, Japan Blood Products Organization, Tokyo, 
      Japan.
FAU - Haino, Katsuyuki
AU  - Haino K
AD  - Biomet K.K., Tokyo, Japan.
FAU - Yunoki, Mikihiro
AU  - Yunoki M
AUID- ORCID: 0000-0002-1548-5894
AD  - Research and Development Division, Japan Blood Products Organization, Tokyo, 
      Japan.
LA  - eng
PT  - Journal Article
DEP - 20181004
PL  - United States
TA  - Transfusion
JT  - Transfusion
JID - 0417360
RN  - 0 (Antibodies, Viral)
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antibodies, Viral/*immunology
MH  - Blood Donors
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/*immunology
MH  - Infant
MH  - Male
MH  - Middle Aged
MH  - Seroepidemiologic Studies
MH  - Serologic Tests
MH  - Young Adult
EDAT- 2018/10/05 06:00
MHDA- 2019/03/26 06:00
CRDT- 2018/10/05 06:00
PHST- 2018/02/28 00:00 [received]
PHST- 2018/07/10 00:00 [revised]
PHST- 2018/07/11 00:00 [accepted]
PHST- 2018/10/05 06:00 [pubmed]
PHST- 2019/03/26 06:00 [medline]
PHST- 2018/10/05 06:00 [entrez]
AID - 10.1111/trf.14908 [doi]
PST - ppublish
SO  - Transfusion. 2018 Nov;58(11):2617-2626. doi: 10.1111/trf.14908. Epub 2018 Oct 4.